Other Events ·
Corbus updates investor presentation with CRB-701 and CRB-913 clinical data
CRBPCorbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. filed a Form 8-K to furnish an updated corporate investor presentation dated October 15, 2026. The filing provides no new material operational or financial updates beyond the previously disclosed clinical trial results for its oncology asset CRB-701 and obesity candidate CRB-913. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and metabolic diseases.